News - ARIZ Precision Medicine

Uncategorized

Ariz Precision Medicine pitch earns $110,000 investment at AngelCon

November 23, 2024

A group of 13 newly minted angel investors put $110,000 into Davis-based Ariz Precision Medicine, a medical research startup developing nanotechnology cancer therapy drugs. https://www.bizjournals.com/sacramento/inno/stories/fundings/2024/11/21/ariz-precision-medicine-angelcon.html...

Uncategorized

ARIZ and NATA Announce Collaboration to develop multiple targeted nucleic acid therapies for cancer treatment

DAVIS, CA, UNITED STATES, November 21, 2024 /EINPresswire.com/ -- The pioneering precision medicine company, ARIZ Precision Medicine (ARIZ), and the Medical Research Council’s Nucleic Acid Therapy Accelerator (NATA), today announced a collaboration to harness their platforms to develop nucleic acid...

Uncategorized

ARIZ Announces Grant of Key US Patent

August 20, 2024

DAVIS, CALIFORNIA, UNITED STATES, August 20, 2024 /EINPresswire.com/ -- ARIZ Precision Medicine, Inc., a preclinical stage biopharmaceutical company developing precision ligand targeted siRNA cancer therapies, today announced the issuance of a broad patent for a highly specific drug candidate (ARIZ...

Uncategorized

ARIZ Precision Medicine wins Golden Tickets to Bakar Labs, sponsored by BrightEdge/American Cancer Society

July 11, 2024

Congratulations to ARIZ Precision Medicine and Catena Biosciences, which have won Golden Tickets to Bakar Labs, sponsored by BrightEdge, the American Cancer Society’s impact investing, innovation, and venture capital arm! https://qb3.org/ariz-and-catena-awarded-golden-tickets-to-bakar-labs-spons...

Uncategorized

ARIZ Precision Medicine adds H. Michael Shepard, PhD to the company’s scientific advisory board

June 24, 2022

https://www.einnews.com/pr_news/578338641/ariz-precision-medicine-adds-h-michael-shepard-phd-to-the-company-s-scientific-advisory-board...

Uncategorized

ARIZ announces Seed round funding

November 3, 2020

ARIZ Precision Medicine, The PRDM Oncogene Targeting Company™ announced that it has secured seed financing bringing total funding to date of $2.5 million. Proceeds will be used to expand the management team as well as continue development of its proprietary PRDM-based product candidates for lung ca...

Uncategorized

ARIZ Precision Medicine Announces Promotion of Brad Niles, Ph.D. to CEO Position

September 19, 2020

DAVIS, California —September 21, 2020-- ARIZ Precision Medicine (ARIZ) today announced the promotion of Brad Niles, Ph.D. to the Chief Executive Officer (CEO) position. Brad has previously served as ARIZ COO and VP of Research and Development since 2016. Former CEO Lonnie Bookbinder wil...

Uncategorized

ARIZ completes CLSI FAST Advisory Program with a virtual Closing Showcase

August 7, 2020

http://califesciencesinstitute.org/fast-spring-2020-showcase-a-virtual-success/?utm_campaign=CLSA%20Bulletin&utm_medium=email&_hsmi=92289318&_hsenc=p2ANqtz-9oNCOUhD4NuhD9OTSKhtB6EROLGpBQC_Rji1gT1XSgGADIwHc6jUhCI4FBKszuX4QP3J69FMrLutp8y8UxCI_vFEmoyA&utm_content=92289318&utm_sour...

News

ARIZ Wins Buzz of BIO!

June 22, 2020

What is the Buzz of BIO Contest? The Buzz of BIO contest provides an excellent opportunity for companies looking to make the connections needed to take their product to the next phase. Twenty biotechs will be nominated in each of the two categories: Pipelines of Promise and Technol...

Uncategorized

ARIZ Precision Medicine honored to participate in Johnson & Johnson Innovation’s Quick Pitch at JPM 2020

February 20, 2020

ARIZ Precision Medicine was honored to be selected as one of nine companies worldwide to participate in Johnson & Johnson Innovation’s Quick Pitch at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2020. ARIZ CEO Lonnie Bookbinder presented information abo...